Pre-Clinical and Clinical Advisors
David Howat, PhD
Project Manager (Development)
David Howat, PhD, gained his PhD at the Kennedy Institute of Rheumatology in London in 1986 on biochemical changes in arthritic joints. After a post doctoral position at the William Harvey Research Institute with Professor Derek Willoughby, studying models of inflammation, he moved to Celltech (1989) where he established the inflammation Pharmacology Department. In 2000, Dr. Howard joined NicOX S.A in France as Director of Pre Clinical Development where he was responsible for six projects. In 2002 he moved to KS Biomedix in the UK as Head of Project Management with responsibility for preclinical development aspects of three biological program- mes. Dr. Howard now runs his own preclinical project management consultancy providing services to smaller biotech companies.
Peter Strong, PhD
Independent Consultant
Peter Strong, PhD, currently advises a variety of small companies (UK, Europe and US) contributing to the selection, development and strategic marketing of respiratory and metabolic / cardiovascular assets and has also completed a number of due diligence assignments for venture capital companies. Previously, Dr. Strong had been with Glaxo, GlaxoWellcome and GSK for 23 years. Most recently he had a pivotal role in the inception of the Respiratory and Inflammatory Diseases Centre of Excellence for Drug Discovery (riCEDD). Following completion of set-up work, his focus was progression of individual assets and shaping the overall portfolio. In GlaxoWell- come, he had leadership roles within the cross-functional matrices which were accountable for the entire Drug Discovery portfolio and specifically within the respiratory diseases therapy area.
« Back